SWOG Cancer Research Network

Recent papers from SWOG Cancer Research Network

1. Patient‐reported outcomes as non‐muscle‐invasive bladder cancer clinical trial endpointsBJU International · 2026
2. Lanreotide for the prevention of postoperative pancreatic fistula (S2408): study protocol for a multicenter randomized controlled trialTrials · 2026
3. Short-period pulsating hot-subdwarf stars observed by TESS in Sectors 61 – 97Publications of the Astronomical Society of Australia · 2026
4. A phase II basket trial of DART SWOG S1609: the salivary gland tumor cohortTherapeutic Advances in Medical Oncology · 2026
5. First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.Journal of Clinical Oncology · 2026
6. S2433: Randomized phase III study of second-line chemotherapy with or without panitumumab for KRAS wild type, locally advanced, or metastatic pancreatic adenocarcinoma.Journal of Clinical Oncology · 2026
7. DART (NCI/SWOG S1609): Comprehensive results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.Journal of Clinical Oncology · 2026
8. Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001.Journal of Clinical Oncology · 2026
9. The association of baseline fatigue and severe cancer treatment toxicity by comorbid conditions: A pooled analysis.Journal of Clinical Oncology · 2026
10. SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAF V600E metastatic colorectal cancer (mCRC).Journal of Clinical Oncology · 2026
11. Prevalence and trends in rural patient enrollment in SWOG cancer clinical trials, 1992-2022.Journal of Clinical Oncology · 2026
12. Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).Journal of Clinical Oncology · 2026
13. Transmission corridors as multifunctional landscapes: New vision and transdisciplinary approaches to shape energy futuresLandscape and Urban Planning · 2026
14. Abstract CT140: Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)Cancer Research · 2026
15. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsJournal of Gynecologic Oncology · 2026
16. Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerJAMA Network Open · 2026
17. Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)Cancer · 2026
18. SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).Journal of Clinical Oncology · 2026
19. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.Journal of Clinical Oncology · 2026
20. Abstract PS3-01-15: Making informed choices on incorporating chemoprevention into care (MiCHOICE): Cluster randomized controlled trial of decision support for breast cancer chemoprevention, SWOG 1904Clinical Cancer Research · 2026